Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Rituximab, and Lenalidomide in Refractory/Recurrent PCNSL and SCNSL
NCT03703167Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jan 2019; status: completed.
02
Drugs
ibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT03703167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703167.